- Reviewed routes
- Injection and nasal spray
- Entry offer
- From $179; supply terms vary
Two routes, one provider to investigate
IVY RX offers NAD+ through distinct injection and nasal product pages. Both currently display a $179 starting offer, but their quantity descriptions differ: the injection says use varies, while the nasal listing identifies thirty sprays. This profile examines the service surrounding those offers; each route has its own product review because an identical headline price does not describe an identical purchase.
The company presents a questionnaire, medical review and pharmacy fulfillment process. A prescription depends on the clinician's decision. We reviewed public information and the rendered pages, without placing an order, submitting a medical history or observing a consultation. That leaves the actual care experience outside the evidence available to this review.
What the entry price establishes
The advertised amount is useful for an initial budget screen, especially because IVY RX describes delivery as included. It does not establish a recurring monthly total. Before comparing this service with a defined monthly plan, obtain the quantity, expected supply period under the prescription, first payment and subsequent payment schedule in writing.
Its injection FAQ describes provider review and injection supplies within the price. The nasal page repeats injection-supply wording, which is a reason to request a route-specific order summary. We do not silently reinterpret that paragraph as verified nasal-kit contents or assume that every public statement applies equally to both formulations.
Access and support have different clocks
IVY RX advertises same-day physician review. That refers to reviewing information, not a guarantee of approval, medication delivery or a clinician answering a later question on the same day. The steps depend on eligibility, clarification of the history, pharmacy processing and the destination. A fast intake should still leave room to ask about the proposed treatment.
Confirm which clinician provides ongoing care, how follow-up is arranged and where to send a medical concern. A mobile app or live support channel describes access infrastructure; neither establishes a measured response time. Also ask what is charged if the assessment ends without a prescription and when an order becomes noncancelable.
Testing claims need product-level documentation
The company displays statements about potency, sterility and endotoxin testing, along with references to licensed or registered facilities. Those are provider claims, not laboratory reports independently inspected by this publication. Ask for the dispensing pharmacy and information applicable to the actual preparation instead of treating a general badge as a batch certificate.
FDA explains that compounded drugs do not receive its premarket approval for safety, effectiveness and quality. Registration of a facility does not change that status. The agency's warning about unsuitable ingredients used in sterile NAD+ preparations provides a concrete reason to ask how the injection product is sourced and prepared.
Where this provider fits
IVY RX expands the comparison for readers considering an online service with more than one NAD+ route. Its main public strengths are separate product pages and a described care pathway. The starting price remains incomplete for annual budgeting until the prescription quantity and renewal terms are known.
The provider's wellness claims and customer reviews do not establish the effectiveness of either finished preparation. Discuss the reason for considering NAD+ with a qualified clinician, particularly when symptoms need evaluation. A useful next step is a written, route-specific quote that can sit beside other offers without hiding differences in formulation or commitment.
Useful distinctions
- Two NAD+ routes documented
- Provider review and delivery described
- Separate product reviews for each route
Limitations to weigh
- Starting offers lack a confirmed monthly denominator
- Nasal page contains injection-related wording
- Testing claims were not independently audited
Sources & further reading
Official pages and evidence consulted for this article. Checked October 11, 2026. Provider pages establish advertised terms; they do not independently establish effectiveness.